MedPal AI plc has acquired eMARx, a provider of digital electronic Medication Administration Record (eMAR) software, for an undisclosed amount. The deal brings eMARx’s medication management platform under the ownership of MedPal AI, which focuses on artificial intelligence-driven tools for the health and social care sector. The transaction has been completed, with eMARx’s operations now integrated into MedPal AI’s broader product suite.
eMARx offers a digital system designed to help care providers manage medications safely and efficiently. Its platform supports residential, nursing, and supported living services by replacing paper-based records with clear digital prompts for care staff, while giving managers real-time visibility into medication administration and compliance. The software aims to reduce paperwork, improve medication safety, and support regulatory adherence. MedPal AI plc develops AI-enabled solutions for care settings, with a focus on streamlining administrative and clinical workflows.
The acquisition is intended to strengthen MedPal AI’s position in the medication management segment of the care market. By adding eMARx’s established eMAR functionality to its existing offerings, MedPal AI can offer a more complete digital workflow for care providers, from medication scheduling to compliance reporting. For eMARx, joining MedPal AI provides access to a larger technology infrastructure and a broader client base, which may accelerate product development and market reach.
The combined entity is expected to focus on integrating eMARx’s medication records with MedPal AI’s analytical tools, potentially enabling more proactive oversight of medication safety across care homes and supported living facilities. The companies have not disclosed further financial terms or specific integration timelines. The acquisition reflects a continued consolidation trend in care technology, where software vendors are combining point solutions into unified platforms to meet rising regulatory and operational demands.